Immunitybio Current Deferred Revenue Over Time
| IBRX Stock | USD 5.04 0.06 1.18% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Immunitybio Performance and Immunitybio Correlation. Immunitybio |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunitybio. If investors know Immunitybio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunitybio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.90) | Revenue Per Share 0.011 | Quarterly Revenue Growth 73.463 | Return On Assets (0.56) |
The market value of Immunitybio is measured differently than its book value, which is the value of Immunitybio that is recorded on the company's balance sheet. Investors also form their own opinion of Immunitybio's value that differs from its market value or its book value, called intrinsic value, which is Immunitybio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunitybio's market value can be influenced by many factors that don't directly affect Immunitybio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunitybio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunitybio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunitybio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Current Deferred Revenue Analysis
Compare Immunitybio and related stocks such as BioLineRx, Ardelyx, and Lexicon Pharmaceuticals Current Deferred Revenue Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BLRX | 1.6 M | 1.6 M | 683.6 K | 1.1 M | 1.1 M | 1.1 M | 963 K | 1.1 M | 1.3 M | 1.3 M | 3 K | 13 M | 13 M | 14.9 M | 15.6 M |
| ARDX | 13.6 M | 13.6 M | 13.6 M | 13.8 M | 16 M | 1000 K | 1000 K | 1000 K | 1000 K | 4.5 M | 4.2 M | 4.7 M | 13.2 M | 7.2 M | 7 M |
| LXRX | (9.4 M) | 119 K | 128 K | 195 K | 1.6 M | 76.5 M | 63.4 M | 40.1 M | 3.4 M | 28.2 M | 28.2 M | 28.2 M | 28.2 M | 32.4 M | 20 M |
| MCRB | 248 K | 248 K | 248 K | 248 K | 1.5 M | 12.1 M | 12.1 M | 12.1 M | 20.4 M | 25.8 M | 22.6 M | 16.8 M | 4.3 M | 7.7 M | 13.6 M |
| PLX | 4.6 M | 6.1 M | 9.4 M | 9.4 M | 6.8 M | 504 K | 837 K | 26.9 M | 9.9 M | 16.3 M | 5.4 M | 8.6 M | 13.2 M | 2.9 M | 2.7 M |
| PDSB | (265.3 K) | (265.3 K) | (265.3 K) | (265.3 K) | (265.3 K) | (265.3 K) | (265.3 K) | (265.3 K) | (265.3 K) | (265.3 K) | (265.3 K) | (265.3 K) | (265.3 K) | (238.7 K) | (250.7 K) |
| CVAC | 5.8 M | 5.8 M | 5.8 M | 5.8 M | 5.8 M | 5.8 M | 5.8 M | 5.8 M | 5.8 M | 7.5 M | 158 M | 55.8 M | 36.8 M | 46.3 M | 56.8 M |
| KRYS | 2.1 M | 2.1 M | 2.1 M | 2.1 M | 2.1 M | 2.1 M | 2.1 M | 2.1 M | 2.1 M | 2.1 M | 5.1 M | 16.2 M | 15 M | 17.3 M | 10.6 M |
| VIR | 8.8 M | 8.8 M | 8.8 M | 8.8 M | 8.8 M | 8.8 M | 8.8 M | 8.8 M | 8.8 M | 6.2 M | 6.5 M | 98.2 M | 15.5 M | 64.9 M | 36.7 M |
| VKTX | 20.3 M | 20.3 M | 20.3 M | 20.3 M | 20.3 M | 1.3 M | 1.3 M | 2.3 M | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (10.5 M) | (9.9 M) |
| TGTX | 258 K | 152.4 K | 152.4 K | 152.4 K | 152.4 K | 152.4 K | 152.4 K | 152.4 K | 152 K | 47.4 M | 152 K | 457 K | 305 K | 300 K | 285 K |
| XFOR | 430 K | 430 K | 430 K | 430 K | 430 K | 430 K | 504 K | 2.6 M | 737 K | 737 K | 737 K | 737 K | 737 K | 847.5 K | 1.2 M |
| MDGL | 345 K | (12 K) | (13 K) | (42 K) | (42 K) | (43 K) | (43 K) | (43 K) | (43 K) | (43 K) | (43 K) | (43 K) | (43 K) | (38.7 K) | (36.8 K) |
Immunitybio and related stocks such as BioLineRx, Ardelyx, and Lexicon Pharmaceuticals Current Deferred Revenue description
Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.My Equities
My Current Equities and Potential Positions
| Immunitybio | IBRX |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
USD 5.04
Additional Tools for Immunitybio Stock Analysis
When running Immunitybio's price analysis, check to measure Immunitybio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunitybio is operating at the current time. Most of Immunitybio's value examination focuses on studying past and present price action to predict the probability of Immunitybio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunitybio's price. Additionally, you may evaluate how the addition of Immunitybio to your portfolios can decrease your overall portfolio volatility.